Nurse-led support for caregivers of older adults with advanced lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This two-phase study investigates the needs of older adults with newly diagnosed locally advanced or advanced non-small cell lung cancer and their primary family caregivers. Phase I uses a cross-sectional design to describe distress, unmet needs, resource use, social support, and health promotion practices. Phase II is a two-group randomized trial comparing the Integrating Nurse-Led and Resource Utilization-Based Caregiver Support Model (ICSM) plus oncology case manager care versus oncology case manager care with usual hospital care, over 12 months, assessing outcomes at baseline and follow-up during treatment. The ICSM includes nurse-led education, counseling, symptom management, coping strategies, social resource use, caregiver self-care, and a web- or LINE-based integrated resource platform. The trial aims to determine whether the ICSM approach improves patient and caregiver outcomes and resource utilization compared with standard care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patient inclusion criteria:

* Older adults with newly diagnosed locally advanced or advanced non-small cell lung cancer.
* Stage III or stage IV non-small cell lung cancer.
* Aware of their cancer diagnosis.
* Preparing to receive anti-cancer medical treatment.
* Able to communicate verbally and complete study assessments.
* Willing to participate in the study and provide written informed consent.

Caregiver inclusion criteria:

* Adult aged 18 years or older.
* Identified by the eligible patient as the fixed primary family caregiver.
* Able to participate in the study together with the patient as a patient-caregiver dyad.
* Willing to participate in the study and provide written informed consent.

Exclusion Criteria:

Patient exclusion criteria:

\- Severe cognitive impairment that prevents completion of study questionnaires or assessments.

Caregiver exclusion criteria:

* Unable to communicate sufficiently to complete study assessments.
* Unable or unwilling to provide written informed consent.

Where it's running

• National Taiwan University Hospital
  Taipei, Taipei, Taiwan Recruiting
• National Taiwan University Cancer Center
  Taipei, Taipei, Taiwan Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery

  This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07837739

• HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC

  This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Wuhan, Hubei · NCT07824882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.